Journal of New Discovery in Microbiology

JOURNAL OF NEW DISCOVERY IN MICROBIOLOGY
Integrity Research Journals

Model: Open Access/Peer Reviewed
DOI: 10.31248/JNDM
Start Year: 2020
Email: jndim@integrityresjournals.org

Submit Manuscript

One-year study on molecular diagnosis of drug-resistant tuberculosis among presumptive tuberculosis patients attending Direct Observed Treatment Shortcourse clinics in Katsina State, North West, Nigeria

https://doi.org/10.31248/JNDM2023.015   |   Article Number: D57432323   |   Vol.2 (2) - April 2024

Received Date: 30 September 2023   |   Accepted Date: 13 April 2024  |   Published Date: 30 April 2024

Authors:  Mohammad A. B.* , Panda T. W. , Kaita I. M. , Yusuf A. , Darma D. A. , Dutsinma U.A. , Aminu A. I. , Iliya S. , Gwarzo F. S. and Mukhtar M. D.

Keywords: Nigeria., Katsina State, Tuberculosis, Drug-Resistant tuberculosis, Xpert MTB/RIF

ABSTRACT

How to Cite Article
Full-Text PDF

Nigeria is one of the 24th high burden countries with drug resistant tuberculosis (DR-TB). This study aimed at determining the prevalence and factors associated with drug-resistant tuberculosis among presumptive tuberculosis patients attending Direct Observed Treatment Shortcourse centres in Katsina State, Nigeria. A one-year retrospective study of presumptive patients screened for Mycobacterium tuberculosis (MTB) and Rifampicin resistant (RR-TB) tuberculosis using Xpert MTB/RIF assay at 14 Genexpert sites in the State between January 1st, 2018 and December 31st, 2018 was conducted. A total of 14,501 presumptive patients were screened for MTB and Rifampicin resistant tuberculosis. The majority (51.4%) were between 25-44 years. Male: Female ratio was 1:0.8. Of the 14,501 clients screened, MTB was detected in 1,750 (12.1%) out of which 35 (0.2%) had DR-TB; Males 30 (0.2%), females 5 (0.03%) respectively. Age (AOR 1.8, 95%CI 1.3-2.6, p = 0.001), symptomatic contact with DR-TB patients (AOR 3.3, 95%CI 2.1-5.1, p. Drug-resistant tuberculosis is in existence in the study area with the prevalence of 0.2%. Drug resistant tuberculosis among presumptive TB patients was high in this study; therefore, urgent steps are needed to avert an impending DR-TB epidemic in the studied area.

Adejumo, O. A., Olusola-Faleye, B., Adepoju, V., Bowale, A., Adesola, S., Falana, A., Owuna, H., Otemuyiwa, K., Oladega, S., & Adegboye, O. (2018). Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria. African Health Sciences, 18(3), 472-478.
Crossref
 
Creswell, J., Codlin, A. J., Andre, E., Micek, M. A., Bedru, A., Carter, E. J., Yadav, R. P., Mosneaga, A., Rai, B., Banu, S., & Ditiu, L. (2014). Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC infectious diseases, 14, 1-12.
Crossref
 
Davies-Bolorunduro, O. F., Nduaga, S. J., Abiodun, A. T., Amuda, B. O., Osuolale, K. A., Atoe, K., & Cadmus, S. (2020). Prevalence of rifampicin resistance among presumptive pulmonary tuberculosis patients within lagos and its environs in South-Western Nigeria. Nigerian Journal of Microbiology, 34(1), 5188-96.
 
Federal ministry of Health Nigeria (FMOHN), (2023). National mid-term up-date presented at Quarterly held at Abuja, Nigeria; Dated 2nd - 4th May, 2023.
 
Geleta, D. A., Megerssa, Y. C., Gudeta, A. N., Akalu, G. T., Debele, M. T., & Tulu, K. D. (2015). Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC microbiology, 15, 1-6.
Crossref
 
International Union Against Tuberculosis and Lung Disease (IUATLD) (2018). Campaign for access to essential medicines. DR-TB drugs under the microscope: sources and prices for drug-resistant tuberculosis medicines. International Union Against Tuberculosis and Lung Disease.
 
Mohammad, A. B., Ibrahim, A., Maifada, A. I., Balogun, M. S., Mohammed, Y., Fagge, H. S., Iliya, S., Ibrahim, A. A., & Mukhtar, M. D. (2021a). Prevalence and Fcators associated with rifanpicin resistance among patients with pulmonary tuberculosis in Kano State, Nigeria. Nigerian Journal of Microbiology, 35(1) 5460-5466.
 
Mohammad, A. B., Iliyasu, G., & Habib, A. G. (2017). Prevalence and genetic determinant of drug-resistant tuberculosis among patients completing intensive phase of treatment in a Tertiary Referral Center in Nigeria. The International Journal of Mycobacteriology, 6(1), 47-51.
Crossref
 
Mohammad, A. B., Usman, A. D., Aminu, A. I., Yakubu, A., Magashi, A, M., Mukhtar, M. D., Kawo, A. H., Iliya, S., Hauwa, Y., Gwarzo, F. S., Abdulkadir, A., Sheshe, A. A., & Taura, D. W. (2020). Molecular diagnosis of urinary Mycobacterium tuberculosis among patients attending Urology Clinic in Aminu Kano Teaching Hospital, Kano, Nigeria. Bayero Journal of Medical Laboratory Science, 5(2), 11-17.
 
Mohammad, A. B., Zakari, F., Yusuf, A. S., Sani, N. M., Wwarzo, A. M., Iliya, S., Gwarzo, F. S., & Mukhtar, M. D. (2021b). Molecular studies on extra-pulmonary tuberculosis among patients attending Aminu Kano Teaching Hospital, Kano, Kano State, Nigeria. Dutse Journal of Pure and Applied Sciences, 7(4a), 1-10
Crossref
 
Muhammed, Y., Sani, N. M., Mienda, B. S., Qossim, M., Sadiq, A. A., & Mohammad, A. B. (2023). Impact of socio-demographic factors on prevalence of rifampicin resistance among patients attending some hospitals in Yobe state of Nigeria. International Journal of Science and Technology Research Archive, 5(1), 14-21
Crossref
 
Narasimooloo, R., & Ross, A. (2012). Delay in commencing treatment for MDR TB at a specialised TB treatment centre in KwaZulu-Natal. South African Medical Journal, 102(6), 360-362.
Crossref
 
National Tuberculosis and Leprosy Control Programme (NTBLCP) (2018). Report on tuberculosis and multidrug resistant tuberculosis diagnosis, treatment and management in Nigeria. National Tuberculosis and Leprosy Control Programme.
 
Van Rie, A., Page-Shipp, L., Scott, L., Sanne, I., & Stevens, W. (2010). Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Review of Molecular Diagnostics, 10(7), 937-946.
Crossref
 
Willeke, K., & Qian, Y. (1998). Tuberculosis control through respirator wear: perforance of national Institute for occupational safety and health-regulated respirators. American Journal of Infection Control, 26(2), 139-142.
Crossref
 
World Health Organization (WHO) (2012). Epidemiology. Global tuberculosis control: Epidemiology, strategy, financing. Pp. 6-33.
 
World Health Organization (WHO) (2013). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2013 global report on surveillance and response. Report no. WHO/HTM/TB/2013.3.
 
World Health Organization (WHO) (2019). Anti-tuberculosis Drug Resistance in the World. Report No.4. Prepublication version. Retrieved 5 May 2019 from whqlibdoc.who.int/hq/2018/ WHO_HTM_TB_2018.394_eng.pdf.
 
World Health Organization Library Cataloguing-in-Publication Data Global tuberculosis report (2014). 1. Tuberculosis - epidemiology. 2. Tuberculosis, Pulmonary - prevention and control. 3. Tuberculosis - economics. 4. Tuberculosis, Multidrug-Resistant. 5. Annual Reports. I.World Health Organization. ISBN 978 92 4 156480 9 (NLM classification: WF 300).
 
World Health Organization (WHO) (2014). library cataloguing-in-publication data global tuberculosis report (2014). Tuberculosis epidemiology. Tuberculosis pulmonary- prevention and control. Tuberculosis economics. Tuberculosis, Multidrug-Resistant. Annual Reports. World Health Organization. ISBN 978 92 4 156480 9 (NLM classification: WF 300).
Copyright © 2025 Integrity Research Journals. All rights reserved.